Form 4: Fennec Pharmaceuticals CFO Receives Stock Options and Restricted Share Units
SEC Form 4 Filing
Robert Andrade, CFO of Fennec Pharmaceuticals, was granted stock options for 100,000 shares and restricted share units for 50,000 shares on May 16, 2024, according to a Form 4 filing.
Summary
- Robert Andrade, the Chief Financial Officer of Fennec Pharmaceuticals, received stock options and restricted share units on May 16, 2024.
- The stock options grant is for 100,000 shares of Fennec Pharmaceuticals common stock, with an exercise price of $7.12 per share.
- The restricted share units award is for 50,000 shares of Fennec Pharmaceuticals common stock.
- Both the stock options and restricted share units were granted pursuant to the Issuer's 2020 Equity Incentive Plan.
- Vesting for both the options and restricted share units begins on May 16, 2025, with one-third vesting on that date.
- The remaining shares vest monthly until April 30, 2027, when 100% of the shares will be vested.
Sentiment
Score: 6
Explanation: The document is a routine disclosure of executive compensation. It's neutral in tone and reflects standard corporate governance practices.
Positives
- The grant of stock options and restricted share units aligns the CFO's interests with those of the shareholders.
- The vesting schedule incentivizes the CFO to remain with the company for the long term.
Industry Context
Equity grants are a common practice in the pharmaceutical industry to incentivize and retain key executives.
Comparison to Industry Standards
- Stock option and RSU grants are standard compensation components for CFOs in publicly traded pharmaceutical companies.
- The vesting schedule of one-third after one year, followed by monthly vesting until fully vested after three years, is a typical vesting structure.
- Comparing the size of the grant to similar companies would require analyzing their executive compensation packages.
Stakeholder Impact
- Shareholders may view the equity grants as a positive sign, aligning management's interests with theirs.
- Employees may see the grants as a sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 05/16/2024 | Date of transaction: Grant of stock options and restricted share units. |
| 05/16/2025 | Vesting Commencement Date: One-third of the shares subject to the option and award may be exercised/released. |
| 04/30/2027 | Date when 100% of the shares subject to the option and award shall be vested/released. |
| 05/21/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.